Charalampos Tsakiris1, Timoleon Siempis1, George A Alexiou2, Anastasia Zikou3, Chrissa Sioka4, Spyridon Voulgaris1, Maria I Argyropoulou3. 1. Department of Neurosurgery, Medical School, University of Ioannina, Ioannina, Greece. 2. Department of Neurosurgery, Medical School, University of Ioannina, Ioannina, Greece. Electronic address: alexiougr@gmail.com. 3. Department of Radiology, Medical School, University of Ioannina, Ioannina, Greece. 4. Department of Nuclear Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Abstract
BACKGROUND: On brain magnetic resonance imaging, both diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) are used to evaluate cerebral tumors. The purpose of this meta-analysis was to evaluate and compare the diagnostic performance of DWI and PWI in differentiating between pseudoprogression and true tumor progression of glioblastoma. METHODS: We performed a systematic review of the PubMed database from January 2000 to December 2019 for relevant studies. After application of specific inclusion and exclusion criteria, the eligible articles were evaluated for methodologic quality and risk of bias using the updated Quality Assessment of Diagnostic Accuracy (QUADAS-2) tool. From the published study results, the pooled sensitivity, pooled specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio and their corresponding confidence intervals (% CI), and the area under the curve, were calculated individually for DWI and PWI. RESULTS: The meta-analysis included 24 studies, with a total of 900 patients. DWI was found to be slightly superior in terms of sensitivity and specificity, 0.88 (% CI 0.83-0.92) and 0.85 (% CI 0.78-0.91), respectively, compared with the respective values of PWI, 0.85 (% CI 0.81-0.89) and 0.79 (% CI 0.74-0.84). On comparison of the overall diagnostic accuracy of the MRI modalities using their respective area under the curve values (0.9156 for DWI, 0.9072 for PWI), no significant difference was demonstrated between the 2. CONCLUSIONS: Both DWI and PWI provided optimal diagnostic performance in differentiating pseudoprogression from true tumor progression in cerebral glioblastoma, and neither technique proved to be superior.
BACKGROUND: On brain magnetic resonance imaging, both diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) are used to evaluate cerebral tumors. The purpose of this meta-analysis was to evaluate and compare the diagnostic performance of DWI and PWI in differentiating between pseudoprogression and true tumor progression of glioblastoma. METHODS: We performed a systematic review of the PubMed database from January 2000 to December 2019 for relevant studies. After application of specific inclusion and exclusion criteria, the eligible articles were evaluated for methodologic quality and risk of bias using the updated Quality Assessment of Diagnostic Accuracy (QUADAS-2) tool. From the published study results, the pooled sensitivity, pooled specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio and their corresponding confidence intervals (% CI), and the area under the curve, were calculated individually for DWI and PWI. RESULTS: The meta-analysis included 24 studies, with a total of 900 patients. DWI was found to be slightly superior in terms of sensitivity and specificity, 0.88 (% CI 0.83-0.92) and 0.85 (% CI 0.78-0.91), respectively, compared with the respective values of PWI, 0.85 (% CI 0.81-0.89) and 0.79 (% CI 0.74-0.84). On comparison of the overall diagnostic accuracy of the MRI modalities using their respective area under the curve values (0.9156 for DWI, 0.9072 for PWI), no significant difference was demonstrated between the 2. CONCLUSIONS: Both DWI and PWI provided optimal diagnostic performance in differentiating pseudoprogression from true tumor progression in cerebral glioblastoma, and neither technique proved to be superior.
Authors: Ramon F Barajas; Prakash Ambady; Jeanne Link; Kenneth A Krohn; Ahmed Raslan; Nadine Mallak; Randy Woltjer; Leslie Muldoon; Edward A Neuwelt Journal: Neurooncol Pract Date: 2022-03-09
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639
Authors: Orkhan Mammadov; Burak Han Akkurt; Manfred Musigmann; Asena Petek Ari; David A Blömer; Dilek N G Kasap; Dylan J H A Henssen; Nabila Gala Nacul; Elisabeth Sartoretti; Thomas Sartoretti; Philipp Backhaus; Christian Thomas; Walter Stummer; Walter Heindel; Manoj Mannil Journal: Heliyon Date: 2022-08-02